LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this first-in-man trial is to determine the safety and tolerability of
ascending single and multiple doses of LEO 22811 in healthy male subjects as well as to
determine the safety and tolerability of single oral doses of LEO 22811 in healthy female
subjects. The trial will be performed in two parts. In Part 1, single doses of LEO 22811 will
be administered to healthy male and female subjects. In Part 2, multiple doses of LEO 22811
will be administered to healthy male subjects.